Biotech leader Glycanostics is revolutionizing cancer diagnostics and creating one-and-only opportunities for forward-thinking investors.

In our last webinar, 50 investors signed up, collectively showing interest in investing nearly €1M. Now, it’s your turn to join!

The final design of the Giasay® Prostate diagnostic test ready for mass production in collaboration with French partner - Firalis.

Advances in breast cancer diagnostics powered by grant funding and new test developments for other cancers.

Key senior management hires to drive commercial milestones.

Don’t miss a chance to reserve your seat and play a part in Glycanostics international growth.

The webinar will be led by Michal Nešpor, partner at Crowdberry.

Find out more about the Glycanostics investment opportunity, which closes on 8 February.

Glycanostics Q&A 28.01.2025

I agree that Crowdberry a.s. may process my personal information (inserted email) for sending newsletters containing updates and news on investment opportunities, and I confirm that I have read the information concerning the processing of personal information and that I have understood it. I also acknowledge that I may revoke my consent at any time by clicking on the link in any newsletter that is marked “unsubscribe” or in the personal profile on the Crowdberry platform.

You must register to sign up for the event.

You must verify your account to sign up for the event

To view this section, please verify your account

You must register before you can access the recording

You must verify your account before you can access the recording

We have just sent you a confirmation email with details about the event. If you wish to cancel your registration, please follow the instructions within the email.

Thank you for signing up!

Sign up for the event

You have already signed up for this event. We are looking forward to seeing you

Glycanostics Q&A 28.01.2025

What will you learn?